Juan Andres - Dec 17, 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Dec 17, 2021
Transactions value $
-$5,928,650
Form type
4
Date filed
12/21/2021, 03:06 PM
Previous filing
Dec 17, 2021
Next filing
Dec 23, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K Dec 17, 2021 Direct F1
transaction MRNA Common Stock Sale -$1.38M -5K -100% $275.68 0 Dec 17, 2021 Direct F1
transaction MRNA Common Stock Options Exercise $142K +10K $14.22* 10K Dec 20, 2021 Direct F1
transaction MRNA Common Stock Options Exercise $61.1K +5K +50% $12.21* 15K Dec 20, 2021 Direct F1
transaction MRNA Common Stock Sale -$4.81M -15K -100% $320.97 0 Dec 20, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -14.29% $0.00 30K Dec 17, 2021 Common Stock 5K $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -10K -25.89% $0.00 28.6K Dec 20, 2021 Common Stock 10K $14.22 Direct F1, F3
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -16.67% $0.00 25K Dec 20, 2021 Common Stock 5K $12.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
F2 This option is fully vested and exercisable.
F3 25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer